



May 12, 2026

Company: KYORIN Pharmaceutical Co., Ltd.
 Representative: Yutaka Ogihara
 Representative Director, President and CEO
 (Security Code: 4569, TSE Prime.)
 Contact: Shota Kikuchi
 Director, Corporate Planning
 Telephone: 03-6374-9702

Notice Regarding Difference Between Financial Forecast and Actual Results

KYORIN Pharmaceutical Co., Ltd. announced that the following differences between the consolidated financial forecast for the interim period of fiscal year ending March 31, 2026, which were announced on May 12, 2025, and the actual consolidated financial results announced today.

1. Difference between consolidated financial results forecast and actual results for the interim period of the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Net profit per share
	Million yen	Million yen	Million yen	Million yen	yen
Previously forecast (A)	127,000	6,100	6,300	4,800	83.55
Actual (B)	126,257	3,567	4,031	3,448	60.03
Change (B-A)	-743	-2,533	-2,269	-1,352	-23.52
Percentage change (%)	-0.6	-41.5	-36.0	-28.2	-28.2
(Ref.) Actuals for the previous period (FY2024)	130,087	12,567	13,219	9,086	158.17

2. Difference between financial results forecast and actual results for the interim period of the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

	Net sales	Operating profit	Ordinary profit	Net profit	Net profit per share
	Million yen	Million yen	Million yen	Million yen	yen
Previously forecast (A)	111,100	6,300	6,800	5,100	88.76
Actual (B)	110,934	4,285	5,048	4,183	72.82
Change (B-A)	-166	-2,015	-1,752	-917	-15.94
Percentage change (%)	-0.1	-32.0	-25.8	-18.0	-18.0
(Ref.) Actuals for the previous period (FY2024)	115,918	12,902	13,706	9,382	163.29

3. Reasons for the differences

Net sales for the current consolidated fiscal year slightly fell short of the previous forecast, as sales of certain mainstay products were lower than expected. Regarding operating profit, ordinary profit, and profit attributable to owners of parent, results were below the previously announced forecast. This was due to a decrease in gross profit reflecting the lower than expected sales, as well as the recording of upfront payments for in-licensed products under research and development expenses.

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.